ATTORNEY FOR WEST. ALSO NEW AT SIX TONIGHT. CARNEGIE MELLON UNIVERSITY LEADERS ANNOUNCING STAFF CUTS AT THE SCHOOL’S SOFTWARE ENGINEERING INSTITUTE. THE CUT REPRESENTS 10% OF THE INSTITUTE’S OVERALL ...

Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, granting Priority Review with a ...

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Savara, with a price target of $11.00. Brisebois covers the Healthcare sector, focusing on stocks such as ...

A new campground designed for off-highway vehicle riders will open June 12 at Lake Vermilion-Soudan Underground Mine State ...

Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a ...

Investing.com - H.C. Wainwright reiterated a Buy rating on Savara (NASDAQ:SVRA) with a $10.00 price target, representing a 95% upside from the current stock price of $5.13. The biotech company has ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the “Company”) (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the ...

Savara represents 4.1% of the fund's AUM. Savara is a clinical-stage biotechnology company specializing developing inhaled biologics for rare respiratory diseases. The company leverages its expertise ...

Savara is a clinical-stage biotechnology company specializing developing inhaled biologics for rare respiratory diseases. The company leverages its expertise in respiratory drug delivery to address ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.S. Food and Drug Administration does not plan to convene an advisory committee for its review of the MOLBREEVI biologics license application, as ...